{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-024422","form_type":"8-K","ticker":"ANIX","cik":"0000715446","company_name":"Anixa Biosciences Inc","filed_at":"2021-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:15.337737+00:00","generated_at":"2026-06-28T23:36:54.799207+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Anixa Biosciences begins patient recruitment for Phase I breast cancer vaccine trial","bullets":["Patient recruitment commenced Oct 1, 2021 for a preventative breast cancer vaccine developed with Cleveland Clinic and DoD.","Phase I open-label, dose-escalation trial in triple-negative breast cancer patients at high risk of recurrence.","Estimated 18–24 participants; trial expected to take approximately one year to complete.","Vaccine targets alpha-lactalbumin; details at ClinicalTrials.gov identifier NCT04674306."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-024422","json":"https://secwatch.observer/filing/0001493152-21-024422.json","markdown":"https://secwatch.observer/filing/0001493152-21-024422.md","text":"https://secwatch.observer/filing/0001493152-21-024422.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/715446/000149315221024422/0001493152-21-024422-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/715446/000149315221024422/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T23:36:54.799207+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}